Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$321.91 USD

321.91
2,654,799

+0.12 (0.04%)

Updated Nov 7, 2024 04:00 PM ET

After-Market: $321.92 +0.01 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks News

Amgen (AMGN) Dips More Than Broader Markets: What You Should Know

Amgen (AMGN) closed the most recent trading day at $231.10, moving -1.39% from the previous trading session.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Amgen (AMGN) Gains But Lags Market: What You Should Know

Amgen (AMGN) closed the most recent trading day at $228.59, moving +1.5% from the previous trading session.

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

The Zacks Analyst Blog Highlights NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen

NVIDIA, Novartis AG, NextEra Energy, The Goldman Sachs Group and Amgen are included in this blog.

Mark Vickery headshot

Top Stock Reports for NVIDIA, Novartis & NextEra Energy

Today's Research Daily features new research reports on 16 major stocks, including NVIDIA Corporation (NVDA), Novartis AG (NVS), and NextEra Energy, Inc. (NEE).

Ligand (LGND) Q4 Earnings Beat, OmniAb Spin-Off in 1H22

Ligand (LGND) reports encouraging fourth-quarter 2021 numbers by beating estimates on both counts. However, royalties decline. The company plans to complete business separation in the first half of 2022.

Mirati (MRTX) Down on Longer Review Period for Adagrasib NDA

The FDA accepts Mirati's (MRTX) NDA for its lung cancer candidate, adagrasib. A decision is expected by Dec 14, 2022.

BridgeBio (BBIO) to Report Q4 Earnings: What's in the Cards?

On BridgeBio Pharma's (BBIO) Q4 earnings call, investor focus is likely to be on updates on the progress of the company's pipeline candidates.

Zacks Industry Outlook Highlights: Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals

Sanofi, AbbVie, Bristol-Myers, Amgen and Vertex Pharmaceuticals are highlighted in this Industry Outlook article.

Will the Rally of These 5 Big Drugmakers Continue in 2022?

Here we discuss five big pharma/biotech companies - SNY, ABBV, BMY, AMGN and VRTX - with the potential to drive investors' wealth higher in 2022 on the back of strong fundamentals.

Sweta Jaiswal, FRM headshot

How Are Biotech ETFs Reacting to These Q4 Earnings Releases?

Let's take a look at some big biotechnological earnings releases to see if these will impact ETFs exposed to the space.

Biotech Stock Roundup: BMY, AMGN, REGN, BIIB's Q4 Earnings & More

Earnings updates from Bristol-Myers (BMY), Amgen (AMGN) and others are among the few key highlights from the biotech sector during the past week.

Amgen (AMGN) Provides Strong Long-Term Outlook, Shares Up

Amgen (AMGN) outlines a strategy to grow its business through the end of this decade on the back of strong demand for existing products and potential of novel pipeline candidates targeting diverse indications.

Stock Market News for Feb 9, 2022

U.S. stocks posted solid gains on Tuesday as investors¿¿¿ sentiment got a boost from a batch of robust corporate earnings.

Ekta Bagri headshot

4 Drug, Biotech Stocks Set to Beat Q4 Earnings Estimates

Let us take a look at some drug/biotech stocks like VIR, MRNA, JAZZ and ACAD that are poised to beat on fourth-quarter earnings.

The Zacks Analyst Blog Highlights Amgen, TakeTwo Interactive, Chegg, Pfizer and BP

Amgen, TakeTwo Interactive, Chegg, Pfizer and BP are included in this blog.

Pfizer (PFE) Q4 Earnings Top, 2022 Sales View Grim, Stock Down

Pfizer (PFE) beats estimates for Q4 earnings but misses the same for sales. The sales guidance for 2022 falls short of investor expectations. Stock declines.

Amgen's (AMGN) Q4 Earnings Top Estimates, Product Sales Fall

Amgen (AMGN) beats Q4 estimates for earnings but misses the same for sales. Higher Other Revenue for manufacturing Eli Lilly's COVID-19 antibody boost sales growth.

Mark Vickery headshot

Mixed Earnings Results for Amgen, TakeTwo; Chegg Jumps on Beat

After Monday's close, more companies reported earnings results, including Amgen, TakeTwo Interactive and Chegg.

Amgen (AMGN) Beats Q4 Earnings Estimates

Amgen (AMGN) delivered earnings and revenue surprises of 5.31% and 0.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Daniel Laboe headshot

The Markets' Tone: Cautiously Optimistic

As more market solidifying data hits the wire, the more the uncertain-fueled January correction unwinds

Centene (CNC) Gears Up for Q4 Earnings: What Lies Ahead?

Centene's (CNC) fourth-quarter results are likely to reflect growth in total membership.

Incyte (INCY) to Report Q4 Earnings: What's in the Offing?

Jakafi sales are likely to have driven Incyte's (INCY) top-line in the fourth quarter.